Oops! It appears that you have disabled your Javascript. In order for you to see this page as it is meant to appear, we ask that you please re-enable your Javascript!
Hospira launches generic bivalirudin ...
Home  »  Community News  »  Hospira launches gen...
Hospira launches generic bivalirudin for injection in US market
Pharma News
, , ,

The US Food and Drug Administration (FDA) has granted marketing approval for Hospira, Inc.’s bivalirudin for injection, a generic version of The Medicines Company’s Angiomax. Branded sales of Angiomax in 2014 in the United States were approximately $500 million.

Hospira’s bivalirudin for injection is available in a single-dose flip-top vial, which matches the current branded offering available. In addition, the company plans to launch a differentiated presentation of the 250 mg bivalirudin for injection in Hospira’s unique ADD-Vantage vial.

“Hospira is excited to launch the first generic of bivalirudin based on a successful challenge of the originator’s patents,” said Philippe Drouet, president, US Commercial, Hospira. “This approval further demonstrates our commitment to bringing safe, lower-cost generic versions of important medications to the market as soon as possible.”

Available as a lyophilized (powder) format, Hospira’s bivalirudin for injection is a direct thrombin inhibitor indicated for use as an anticoagulant in patients: ith unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA); Undergoing percutaneous coronary intervention (PCI) with provisional use of glycoprotein IIb/IIIa inhibitor (GPI) as in the REPLACE-2 study; With, or at risk of, heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis syndrome (HITTS), undergoing PCI.

Bivalirudin is intended for use with aspirin.

Hospira’s specialty injectable pharmaceuticals (SIP) offering includes approximately 200 generic injectable drugs in many dosages and formulations. In addition, many of its products are available in popular differentiated presentations, several of which are proprietary, such as the ADD-Vantage drug delivery system and Carpuject™ prefilled syringes. Therapeutic segments include analgesia, anesthesia, anti-infectives, cardiovascular, oncology, emergency and other areas. Hospira also has robust pipelines of both generic and biosimilar drugs.

Hospira, Inc. is the world’s leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars.

Leave a reply

You must be logged in to post a comment.